Figures from the Editors selected issue highlights will be displayed each month in the journal image carousel on the BJCP homepage http://bpspubs.onlinelibrary.wiley.com/hub/journal/10.1111/(ISSN)1365-2125/.
It is very simple! We're getting older and that means we're getting more health problems. However, though the longevity trend has been ongoing for decades, drug development and treatment have not really caught up. The October issue of BJCP contains a Themed Issue on ‘Medicines development to improve clinical outcomes in an increasingly older and multi‐morbid patient population’, a timely and important topic.
The first editorial provides a bookend context to the issue and an overview of its broad coverage; opportunities in pharmaceutical development, regulation, prescribing and dispensing, as well as emerging technology that may alter the prescriber‐patient interface. It's fantastic and the perspective is fresh – we hope you enjoy it!Insert link here to Stegemann editorial (ED‐00716) when ready.
Demographics in the 2020s—Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life
Sven Stegemann, Diana van Riet‐Nales and Anthonius de Boer
DOI: 10.1111/bcp.14511
The clinical and therapeutic challenge of treating older patients in clinical practice
Regina Roller‐Wirnsberger, Bettina Thurner, Christian Pucher, Sonja Lindner and Gerhard Hubert Wirnsberger
DOI: 10.1111/bcp.14074
Medication use among older people in Europe: Implications for regulatory assessment and co‐prescription of new medicines
Anna Strampelli, Francesca Cerreta and Katarina Vučić
DOI: 10.1111/bcp.14462
There is also an unrelated collection of original research articles in this issue that are well worth a read. Two of these are at the other end of the life spectrum when compared with the themed issue:Engbers and colleagues from The Netherlands, examined enantiomer specific ibuprofen pharmacokinetics in neonates to conclude that dose adjustment per day of life is required, in addition to weight adjusted dosing, to achieve a desired level of equal therapeutic exposure (with the intention of treating a patent ductus arteriosus, PDA).
Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus
Aline G.J. Engbers, Robert B. Flint, Swantje Völler, Johan C.A. de Klerk, Irwin K.M. Reiss, Peter Andriessen, Kian D. Liem, Pieter L.J. Degraeuwe, Siska Croubels, Joske Millecam, Karel Allegaert, Sinno H.P. Simons and Catherijne A.J. Knibbe
DOI: 10.1111/bcp.14298
Rare genetic diseases can sometimes be treated by supplementation, administration of which could start prenatally. Körber and colleagues, from Germany, present promising results from first‐in‐human and phase II trials of Fc‐EDA, an ectodysplasin A1 replacement protein to treat the rare disease X‐linked hypohidrotic ectodermal dysplasia (XLHED), an inherited deficiency of the signalling protein EDA1. A worthy project and a promising potential treatment, especially when administered intra‐amniotically.
Safety and immunogenicity of Fc‐EDA, a recombinant ectodysplasin A1 replacement protein, in human subjects
Iris Körber, Ophir D. Klein, Patrick Morhart, Florian Faschingbauer, Dorothy K. Grange, Angus Clarke, Christine Bodemer, Silvia Maitz, Kenneth Huttner, Neil Kirby, Caroline Durand and Holm Schneider
DOI: 10.1111/bcp.14301
Alqdwah‐Fattouh and colleagues from Spain, address the use of antidepressants in the acute myocardial infarction (AMI) patient population, a hot topic since the SADHEART trial published in 2002. This retrospective nested case–control study of 24,155 incident AMI cases with 120, 775 controls concluded a lower risk in those patients taking antidepressants that interfered with serotonin reuptake or receptor activity. The interface between psychiatric co‐morbidities and therapeutics and cardiovascular disease remains a vital domain and merits further such work to improve holistic patient care.
Differential effects of antidepressant subgroups on risk of acute myocardial infarction: A nested case–control study
Rasha Alqdwah‐Fattouh, Sara Rodríguez‐Martín, Francisco J. de Abajo, Diana González‐Bermejo, Miguel Gil, Alberto García‐Lledó and Francisco Bolúmar
DOI: 10.1111/bcp.14299
Pupillography can be a useful tool to study autonomic nerve activity during antipsychotic treatment. However, polymorphisms in the genes related to the pharmacokinetics and pharmacodynamics of antipsychotic drugs might influence results of such studies. Koller and colleagues from Madrid, Spain, studied 46 polymorphisms in relevant genes as well as pharmacokinetics and pupil contraction after the administration of aripiprazole and olanzapine to healthy volunteers and were able to identify several factors that might influence pupillography results.
The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple‐dose trial
Dora Koller, Miriam Saiz‐Rodríguez, Pablo Zubiaur, Dolores Ochoa, Susana Almenara, Manuel Román, Daniel Romero‐Palacián, Alejandro de Miguel‐Cáceres, Samuel Martín, Marcos Navares‐Gómez, Gina Mejía, Aneta Wojnicz and Francisco Abad‐Santos
DOI: 10.1111/bcp.14300
This issue of BJCP ends with three interaction studies; two real studies and one simulation:
Kirigaya et al., from Japan, present two open‐label crossover studies designed to investigate the effects of a strong cytochrome P450 inhibitor and that of a strong inducer on the PK of a nonsteroidal mineralocorticoid receptor blocker (esaxerenone – a Japanese approved therapeutic for hypertension). PK data showed significant increases in plasma concentration with Itraconazole, an inhibitor (AUCinf + 53.1%), and significantly decreased concentration with rifampicin, an inducer (AUCinf ‐ 68.8%). The authors conclusion to advise caution when co‐prescribing esaxerenone with CYP450 inducers or inhibitors is well justified.
Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
Yoshiaki Kirigaya, Masanari Shiramoto, Tomoko Ishizuka, Hinako Uchimaru, Shin Irie, Manabu Kato, Takako Shimizu, Takafumi Nakatsu, Yasuhiro Nishikawa and Hitoshi Ishizuka
DOI: 10.1111/bcp.14302
Goulooze and co‐authors, from the Netherlands, present four population PK phase I studies for DLR‐17822, a novel cholesteryl ester transferase protein inhibitor in clinical development to treat dyslipidaemia, lowering LDL and raising HDL. There was a strong food effect at time of administration that should be taken into account in ongoing drug development.
The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL‐17822 in healthy male volunteers
Sebastiaan C. Goulooze, Annelieke C. Kruithof, Shanavas Alikunju, Anirudh Gautam, Jacobus Burggraaf, Ingrid M.C. Kamerling and Jasper Stevens
DOI: 10.1111/bcp.14297
And finally, Adiwidjaja et al, writing from Australia, convey results of PBPK modelling to simulate interactions between various medications and use of Schisandra sphenanthera, a staple of traditional Chinese medicine containing a CYP450 inhibitor. Their PBPK model predicts an impressive 3‐fold increase in bosutinib due to this drug–drug interaction; they also modelled a 2‐fold increase in midazolam and tacrolimus exposure. I truly hope this interesting study will one day be confirmed by actual clinical studies. It will further grow confidence in the actual predictive value of studies such as these.
Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach
Jeffry Adiwidjaja, Alan V. Boddy and Andrew J. McLachlan
DOI: 10.1111/bcp.14303
Issue highlights 86–10. Br J Clin Pharmacol. 2020;86:1897–1898. 10.1111/bcp.14549
